Mangtani and colleagues 1 have created a model to examine whether pneumococcal immunization in people Ͼ64 years in a developed country setting is cost-effective. The key elements in any such programme would be: effectiveness in preventing pneumococcal disease; the frequency of such events; the costs of the immunization programme-vaccine cost and payments to general practices (or others)-the costs avoided from reduction of disease and hence of events such as hospital admissions; and the net balance of costs and benefits. In their model, data on some of these elements are more certain than others.
colleagues use a figure of 50% efficacy against illness and death from pneumococcal bacteraemia. This figure seems to be a compromise between the results of meta-analyses of randomized controlled trials 3, 4 which show 38% protection (but with 95% confidence interval (CI) of Ϫ4 to 63% overlapping no benefit), whereas observational studies report mean benefit of 55% (44-64%) if only studies in the elderly and chronic diseased are used (i.e. excluding groups such as patients with HIV and US Navajos). It does not seem to fit with their previous review, 5 which concluded that there was no evidence of a mortality reduction in developed countries.
As regards the much commoner manifestation of pneumonia, the authors note that three meta-analyses of the trials of the polysaccharide vaccine in elderly people in developed countries show no protection. Indeed, the latest and one of the better observational studies 6 found a slight increase in pneumonia (hazard ratio 1.14, 95% CI 1.02-1.28). However they then assume some protection and hence cost savings from a reduction in non-bacteraemic pneumonia, using a figure of 37.5% reduction in both bacteraemia and pneumonia (Table 2) . They do substantiate this with corresponding figures assuming no protection against pneumonia, which show a rather different picture.
Government advice in the UK takes an unjustifiably favourable view of the efficacy of the vaccine-'overall efficacy in preventing pneumonia is probably 60-70%'. 7 Most (8 of 13) of the supporting references are epidemiological, and the only meta-analysis of evidence of efficacy cited 8 failed to find evidence of efficacy in high-risk groups, being based on randomized controlled trials (RCTs). So in effect, the UK Government has based its advice on observational studies, while seeming to ignore the RCTs.
Previous economic evaluations have chosen to rely on efficacy data from observational studies rather than trials. Sisk and colleagues 9 used a base case efficacy of 80% protection against pneumonia, which seems to have been based mainly on one observational, case-control study, 10 which had a much wider age range than just the elderly, though mean age was 68 years. Ament and colleagues 11 asserted that pneumococcal immunization would be cost-effective if it only reduced invasive disease, but assumed a reduction in pneumococcal bacteraemia of 60% and that immunization also gave some protection against pneumonia. The RCTs do not support these assumptions.
The model created by Mangtani and colleagues provides a useful contribution to the literature, because it can be used to test other assumptions. It would be interesting to re-run the model with the higher vaccine cost, the new discount rates, and 12 The problem with pneumococcal immunization is that, for elderly people in developed countries, the evidence suggests some protection against the uncommon outcome of invasive disease (not quite statistically significant in the RTCs but more marked in the observational studies) but no protection against the commoner pneumonia. 13 
